Characteristics of Patients With Ulcerative Colitis Initiating Vedolizumab Therapy in Real-World Clinical Practice

被引：0
|
作者：
Khalid, Javaria M. [1 ]
Reynolds, Matthew [2 ]
Alam, Naufi L. [3 ]
Don, O'Hara [2 ]
Smyth, Michael D. L. [1 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, London, England
[2] Evidera, Lexington, MA USA
[3] Evidera, London, England
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2015年 / 110卷
关键词：
D O I：
10.14309/00000434-201510001-01946
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1946
引用
收藏
页码：S825 / S825
页数：1
相关论文
共 50 条
  • [21] Real-world effectiveness of adalimumab in patients with ulcerative colitis
    Armuzzi, A.
    Taxonera, C.
    Panes, J.
    Lakatos, P.
    Fisseha, N.
    Pappalardo, B.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S280 - S282
  • [22] Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany
    Bokemeyer, B.
    Picker, N.
    Kromer, D.
    Rosin, L.
    Patel, H.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I466 - I467
  • [23] Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany
    Bokemeyer, B.
    Picker, N.
    Kromer, D.
    Rosin, L.
    Patel, H.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I466 - I467
  • [24] Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
    Teich, Niels
    Gruemmer, Harald
    Joergensen, Eric
    Liceni, Thomas
    Holtkamp-Endemann, Frank
    Fischer, Tim
    Hohenberger, Susanne
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (21) : 2852 - 2863
  • [25] Golimumab in real-world practice in patients with ulcerative colitis:Twelve-month results
    Niels Teich
    Harald Grümmer
    Eric J?rgensen
    Thomas Liceni
    Frank Holtkamp-Endemann
    Tim Fischer
    Susanne Hohenberger
    World Journal of Gastroenterology, 2020, (21) : 2852 - 2863
  • [26] Comparison of Real-World Healthcare Resource Utilization Among Advanced Therapy-Experienced Patients With Ulcerative Colitis Initiated on Ustekinumab or Vedolizumab
    Zhdanava, Maryia
    Kachroo, Sumesh
    Boonmak, Porpong
    Burbage, Sabree
    Shah, Aditi
    Korsiak, Jill
    Lefebvre, Patrick
    Kerner, Caroline
    Pilon, Dominic
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S15 - S15
  • [27] REAL-WORLD EVIDENCE OF VEDOLIZUMAB THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: FECAL CALPROTECTIN A VALID BIOMARKER OF MUCOSAL INFLAMMATION
    Cicerone, C.
    Luppino, I.
    Erboso, M.
    Paese, P.
    Leo, P.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E239 - E239
  • [28] REAL WORLD EVALUATION OF PROLONGED CLINICAL RESPONSE WITH VEDOLIZUMAB IN CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN A PRIVATE PRACTICE SETTING
    Ritter, Timothy E.
    Fourment, Chris
    Van Anglen, Lucinda J.
    Okoro, Tracy C.
    Hardin, Thomas C.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S74 - S74
  • [29] Real World Experience With Vedolizumab as First-Line Therapy for the Treatment of Ulcerative Colitis
    Ritter, Timothy E.
    Mehta, Samantha A.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S439 - S439
  • [30] REAL WORLD EVALUATION OF PROLONGED CLINICAL RESPONSE WITH VEDOLIZUMAB IN CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN A PRIVATE PRACTICE SETTING
    Ritter, Timothy E.
    Fourment, Chris
    Van Anglen, Lucinda J.
    Okoro, Tracy C.
    Hardin, Thomas C.
    GASTROENTEROLOGY, 2018, 154 (01) : S105 - S105
12345